In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

Perfuze, a medtech has raised €22m. With the infusion, the company will release its catheters to select stroke centres in the US.

Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case Reports in Clinical Medicine, 14, 123-129. doi: 10.4236/crcm.2025.143016 .

The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.

The study, published March 12 in JAMA Network Open, compared the newly approved tenecteplase in a single quick injection to alteplase, the stroke treatment that has been used for decades and requires ...

Coinciding with the FDA’s clearance for the catheter, Perfuze has also completed a €22m ($24m) financing round.

Perfuze, an Ireland-based developer of catheter-based aspiration technology for the treatment of acute ischemic stroke, ...

A clot-busting drug recently approved to treat acute ischemic strokes (AIS) that can be delivered quickly works as well as a ...

Perfuze, a leading medical device company dedicated to advancing stroke treatment, today announced that it has received FDA 510(k) clearance for its Ziplinetm Access Catheters. This regulatory ...

Perfuze, a leading medical device company dedicated to advancing stroke treatment, today announced that it has received FDA ...

Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly ...

The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in adults.